Document is current
Any future updates will be listed below
-
Authors
Abdallah, Nadine H. https://orcid.org/0000-0001-9195-1589
Binder, Moritz https://orcid.org/0000-0001-9014-9658
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Greipp, Patricia T.
Kapoor, Prashant https://orcid.org/0000-0002-4342-364X
Dispenzieri, Angela https://orcid.org/0000-0001-8780-9512
Gertz, Morie A.
Baughn, Linda B. https://orcid.org/0000-0001-5229-4897
Lacy, Martha Q.
Hayman, Suzanne R.
Buadi, Francis K. https://orcid.org/0000-0003-3214-0203
Dingli, David https://orcid.org/0000-0001-7477-3004
Go, Ronald S. https://orcid.org/0000-0002-8284-3495
Hwa, Yi L.
Fonder, Amie L.
Hobbs, Miriam A.
Lin, Yi https://orcid.org/0000-0002-1556-6416
Leung, Nelson
Kourelis, Taxiarchis https://orcid.org/0000-0001-8573-9434
Warsame, Rahma
Siddiqui, Mustaqeem A. https://orcid.org/0000-0002-4640-7311
Kyle, Robert A.
Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
Ketterling, Rhett P.
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
- License Information
-
More Information
Article History
Received: 12 August 2021
Revised: 7 December 2021
Accepted: 12 January 2022
First Online: 31 January 2022
Competing interests
: PK received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. MQL received research funding from Celgene. NL serves on an advisory board for Takeda Pharmaceuticals. RF served as a consultant for Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Karyopharm, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK, and AbbVie, and is on the scientific Advisory Board for Adaptive Biotechnologies, Caris Life Sciences and OncoTracker. SKK served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. The remaining authors declare no competing financial interests.
